# Nanjing Leads Biolabs

Source: https://onco.cc/companies/nanjing-leads-biolabs/  
OnCo record `nanjing-leads-biolabs` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nanjing Leads Biolabs is a China-based biotechnology company running 8 late-stage cancer trials of LBL-024 and LBL-034 in triple-negative breast cancer, non-small-cell lung cancer and hepatocellular carcinoma.

## Summary

Nanjing Leads Biolabs, based in Nanjing, China, is a biotechnology company. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials, testing LBL-024 and LBL-034 in triple-negative breast cancer, non-small-cell lung cancer, hepatocellular carcinoma, oesophageal cancer and multiple myeloma. The largest, NCT05170958 (A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumours), plans to enrol 396 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Nanjing Leads Biolabs Co.,Ltd
- Tags: ctgov-sponsor
- HQ: Nanjing
- Type: biotech
- Website: https://www.leadsbiolabs.com

## Sources

- Official website: https://www.leadsbiolabs.com
- ClinicalTrials.gov: trials led by Nanjing Leads Biolabs: https://clinicaltrials.gov/search?lead=Nanjing%20Leads%20Biolabs%20Co.%2CLtd

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- trials: [A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]](https://onco.cc/trials/nct06783647/), [A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]](https://onco.cc/trials/nct07111546/), [A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma](https://onco.cc/trials/nct07791758/), [A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma](https://onco.cc/trials/nct06049290/), [A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors](https://onco.cc/trials/nct05170958/), [A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]](https://onco.cc/trials/nct07331155/), [A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]](https://onco.cc/trials/nct07390383/), [A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer](https://onco.cc/trials/nct07042802/), [A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer](https://onco.cc/trials/nct07281976/)

---
JSON: https://onco.cc/api/v1/entities/nanjing-leads-biolabs.json